Shefali Agarwal
Directeur Général chez VALERIO THERAPEUTICS
Fortune : 40 596 $ au 30/04/2024
Postes actifs de Shefali Agarwal
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FATE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/07/2019 | - |
| Independent Dir/Board Member | 15/07/2019 | - | |
| GRITSTONE BIO, INC. | Directeur/Membre du Conseil | 01/06/2021 | - |
| Independent Dir/Board Member | 01/06/2021 | - | |
| VALERIO THERAPEUTICS | Président | 29/07/2021 | - |
| Directeur Général | 06/04/2022 | - | |
| President | 06/04/2022 | - | |
| Directeur/Membre du Conseil | 01/06/2021 | 29/07/2021 | |
| Independent Dir/Board Member | 01/06/2021 | 29/07/2021 |
Historique de carrière de Shefali Agarwal
Anciens postes connus de Shefali Agarwal
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EPIZYME, INC. | Directeur Technique/Scientifique/R&D | 01/06/2018 | 06/04/2022 |
| SQZ BIOTECHNOLOGIES COMPANY | Directeur Technique/Scientifique/R&D | 01/07/2017 | 01/05/2018 |
Formation de Shefali Agarwal
| Karnataka University | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
| Merrick School of Business | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
| Inde | 2 |
| France | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| Entreprise privées | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Shefali Agarwal
- Expérience
